As the common adage goes, cancer is not just one disease, but more like millions of individual conditions. If research continues along the directions many of the scientists speaking at San Francisco State University’s annual Personalized Medicine 3.0 conference predict, a cancer diagnosis may initiate a journey through a medical flowchart. Patients, geneticists, and oncologists will examine a person’s DNA makeup for thousands of possible variations which may affect the severity of his/her disease and the likelihood of its responding to particular pharmaceutical formulations.
Dr. Michael Goldman, chair of SFSU’s biology department, highlighted this emerging concept as the event’s theme while attendees enjoyed a luscious healthy fruit and pastry feast. Soon afterwards, David Duncan, author of Experimental Man and director of UC Berkeley’s Center for Life Science Policy, regaled us with tales from his genome. Duncan paid for complete analysis of his entire genetic makeup, which proved that he was basically healthy except for a predisposition to heart problems if he continued to gain weight. Responding to this news by losing ten pounds, Duncan advocated the potential positive consequences of learning more biologically about ourselves.
Other researchers continued the trend of linking basic science research to practical and clinical applications, including Dr. Steven Anderson, chief scientific officer of Monogram Biosciences/Labcorp, who took part in a panel discussion on diagnosing cancer. Anderson discussed mutation profiling of the DNA of cancer tumor cells to determine exactly which genes were altered or under/overexpressed in a particular person’s condition, with the pathology of four basic subtypes of breast cancer as an example. As a leader in the molecular oncology field, he helped develop many of the diagnostic assays making this level of genetic analysis possible, relying on molecular biology and immunology methods which identify mutations and gene expression levels.
Another panel speaker, Dr. Jeffrey Lawrence of Roche Molecular Systems, related how the pharmaceutical industry now works towards coordinating the development of diagnostic tests for one’s cancer subtype with the production of a specific medicine for its treatment. Also, Richard Shippy of Affymetrix, described new microassays which can detect the presence of certain alleles (particular forms of a gene) to identify a potentially pathological loss of genetic diversity in a patient’s cells. And, finally, just before lunch, Dr. Jerald Radich of the Fred Hutchison Cancer Research Center elucidated methods of determining the likelihood that a patient’s acute disease will return after a period of remission. The research he referenced held implications for metastatic melanoma skin cancer and acute myeloid leukemia, two types of cancer where medical science still has a long way to go when it comes to improving long-term survival rates.









